22R2 Customer Webinar For All

July 7, 2022



CDMS Product Managers



Sharon Lin


John Roeckel (JB)

Product Manager

Data Entry, Query Handling



Veeva Vault Release Schedule




22R2 Release Calendar

| Sun | Mon | Tue | Wed | Thu | Fri | Sat |
|-----|-----------------|-----|-----|---|-----------------------------------|-----|
| JUL | 04 | 05 | 06 | 07 22R2 Release Webinar 9 AM PT - All Customers 10 AM PT - Studio, Admin, Coder | 08 22R2 Pre-Release Upgrade | 09 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| | Validation Docs | | | | | |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| | | | | | | |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
| | | | | | | |
| AUG | 01 | 02 | 03 | 04 | 05 | 23 |
| AUG | | | | | 22R2 General Release Upgrade | |

Customer Validation

22R2 Release Dates






Available Resources

https://cdmshelp.veeva. com/lr/rn/general-releas es/22r2/

- Important Dates
- Notifications Opt-In
- Feature information
- Pre- Release
 Information
- Release Information
- Release Impact Assessment (RIA)


22R2 Feature Summary





Local Labs

New Lab Architecture - Global Versionless Local Labs



Global Versionless Labs

- Overview
 - The new Global Local Lab Architecture will directly consume Lab units, codelists, precision/length from Local Lab module and no longer from Studio for Lab eCRFs.
 - No more synching of the Lab Units/Codelists with Studio
 - No more increasing Casebook Versions, Studio Deployments, and Retro-amendments
 - Yes to Post Go Live changes to Unit Conversion Factors, Unit Standard changes, and increases to Precision and Length
 - Applicable to new studies created after 22R2, existing Studies will have to migrate. Migration will be performed by Veeva Services team.
- Note: Global Labs is NOT supported in Utilities, but studies will be able to use listings that does not contain clinical lab data. The Study Data Extract (SDE) will support both Global and non-GLobal studies.
- Use case

Be able to add/update Lab Units and Codelists without creating a new casebook version, deploying, and performing a retro- amendment for each study.



No

Visibility Data Manager, Lead Data Manager, Lab Manager, Study Designers Configuration

N/A

Dependencies

Labs Enabled New Studies Database Model 2



Copyright © Veeva Systems 2022

Increasing Precision and Length

Overview

- Precision and Length can be increased when analyte is marked "in use"
 - For new studies on the Global Labs, increasing precision and length is only done in the Lab Module
 - For existing studies, increases must be done in Local Labs and Studio to stay in sync
 - Studio will now allow increases to Precision and Length

Use case

I abo

Realizing that the Precision and Length was inaccurate after objects (eg. Lab Panels) were already associated to it, and still be allowed to update it.

| SYSTEM SETTINGS | Analyte Library | | | | | | | |
|----------------------------------|------------------------|----------------------------|------------|----------------------------|-------------------------|--------|--------|-----------|
| Analyte Library | + Add New Analyte Done | Import Analytes Search | Analytes Q | Created By: All 👻 Modified | d By: All 👻 In Use: All | ¥ | | |
| System General Settings | Analyte | Label | Data Type | Measurement Type | Codelist | In Use | Length | Precision |
| LAB SETTINGS | AAA | AAA | Unit | HDL_Unit | | | | |
| Lab Locations & Normal Ranges | AAB | AAB | Number | | | | 14 | 3 |
| Reports Mass Updates | ALB | Albumin | Unit | ALB_Unit | | IN USE | 8 | 2 |
| | ALT | Alanine Aminotransferase | Unit | ALT_u | | IN USE | 14 | 2 |
| STUDY SETTINGS | AMY | Amylase | Unit | AMY_unit | | | 8 | 2 |

Day 1 Impact to Clinical Teams

No

Visibility Data Manager, Lead Data Manager, Lab Manager

Configuration N/A

Dependencies

Labs Enabled New Studies Database Model 2

Archiving Lab Units/Codelists

- Overview
 - The Lab Units and Codelists will now be archived instead of deleted.
 - Lab Units and Codelists Name will be locked once saved. Labels, Unit Conversions, and Unit standards can be updated.
 - Once archived, Lab Normals will not be able to select the unit or codelist item (new and existing studies). Still preserved for previous Lab Normals, but once in edit mode, will not be able to select the archived item
 - Once archived, Labe eCRFS will not be able to select the unit or codelist item. Still
 preserved for existing Lab eCRFs, but once in edit mode, will not be able to select the
 archived item.
 - For the older architecture (Non Global) existing studies, the Unit/Codelist item will still need to be hidden in Studio

Edit Lloit

Use case

Be able to archive a unit or codelist item

that is no longer needed.

| Name | | | | Unit Type | | Label | | | |
|----------|------------|---------------------------------|-----|-------------|--------------|--------|--------------------------|-------------|--|
| Calcium | n_unit | | | DENSITY | • | Calci | ium_Unit | | |
| External | ID | | | Status | v | Descri | iption | | |
| | ement Unit | S d Measurement Units | | | | | | | |
| | Standard | Name | Lab | el | Abbreviation | Unit C | Conversion | External ID | |
| н | Standard | Name mmol_L | | el nol/L | Abbreviation | Unit C | Conversion | External ID | |
| | | | | nol/L | Abbreviation | | Conversion uev *.0555 | External ID | |
| н | | mmol_L | m | nol/L | Abbreviation | Svalu | | External ID | |

No

Visibility Data Manager, Lead Data Manager, Lab Manager

Configuration N/A

Dependencies

Labs Enabled New Studies Database Model 2

Mass Update: Preview/Update Translated Value

- Overview
 - With the allowance of Post Go Live updates to unit conversion factors and standards, _ existing forms who used the old unit conversion factors or different standards need to be updated to the new unit conversion factor or standards. A Mass update will need to be run on all the existing eCRFs to update to the new unit conversions/or standards.
 - Mass updates to Preview and Update Translated Values are only available for Studies on _ Global Labs.
 - Locked and Frozen items will not be updated with the mass update. If it needs to be updated, unlock or unfreeze and then run the mass update again.

*Note - Change in the Report and Job Names for Mass Updates

Use case

Be able to easily update a unit conversion

or unit standard Post Go Live

| New Job | × | Configuration |
|--|---|--------------------------------|
| Туре | | N/A |
| NEW / MERGE LAB LOCATIONS | - | |
| Preview New/Merge Lab Locations Update New/Merge Lab Locations LAB NORMALS | | |
| Preview Outdated Lab Normals Update Outdated Lab Normals | Þ | |
| Site Override Lab Normals Report | | Dependencies |
| TRANSLATED VALUES (CONVERSION FACTORS) Preview Translated Values | 0 | Labs Enabled New Studies on |
| Update Translated Values 05/11/2022 3:17 PM PD | T | Global Database Model 2 |

Copyright © Veeva Systems 2022

Day 1 Impact to **Clinical Teams**

No

Visibility

Data Manager,

Lead Data

Manager, Lab

Manager

Audit Trail - Translated Values

- Overview
 - The Audit trail in the Data Entry now shows translated values if the item is a unit. This applies to Lab Forms and non - Lab Forms
- Use case

Be able to see the translated value display in the Audit trail. Especially beneficial when a Mass Update - Update Translated Value job has been run on eCRFs.

| tem Audit Trail | | × |
|-------------------------|---|---|
| Timestamp | Username | Event Description |
| 7/6/2022 4:21:42 PM PDT | Sharon Lin (sharon.lin@cdmspm.com) | Translated value set to "140 mmol_L". Reason for change: "Changes prior to submission". |
| 7/6/2022 4:21:42 PM PDT | Sharon Lin (sharon.lin@cdmspm.com) | Value entered "140 mEq_L". Reason for change: "Changes prior to submission". |
| 7/6/2022 4:21:31 PM PDT | System on behalf of Sharon Lin (sharon.lin@cdmspm.com) | Item : VV-007793 created |

Yes

Visibility Site Users, Data Manager, Lead Data Manager

Configuration N/A

Dependencies

Labs Enabled Database Model 2

Disable Unit Selection for Lab Results when Lab Normals are Present

- Overview
 - Configure Lab eCRFs so a Site can not update the Lab Result unit. The Lab result unit will be the approved Lab Normal Unit.
- Use case

Some sponsors do not want the Site to update the Lab Result unit. If the Lab Result unit is incorrect, the Site can add an Override Lab Normal unit (if configured).

Labs

| SYSTEM SETTINGS | Study General Settings | | | | | | |
|----------------------------------|--|-------------------------|--------------|------------|-----------------------|--------------------|----------------------|
| Analyte Library | All Studies > Salmoniq 22R2_DEV1 - | Screening (06-Jul-2 | , | | 10:00 | | All changes saved |
| System General Settings | | Collection Date | īme | – OR – | | Not Performed | |
| LAB SETTINGS | Study Settings | Lab Location | | | 38 Queen Street Londo | n NW50 4RM, United | d Kingdom |
| Lab Locations & Normal Ranges | Fire Out-of-range Queries by Default Yes No | Age Sex | C | 27 Male | Years | • | |
| Reports Mass Updates | Allow Site Overrides for Lab Normals () Yes No | Liver | | | | | |
| STUDY SETTINGS | Default Day and Month for Age calculations 0 July | Missing Result | Analyte | | Lab Result | | Normal |
| Study General Settings | | | Albumin | | 1 | g/L · | •• 34.00 - 55.00 g/L |
| Site Lab Assignment | Disable Unit selection for Lab Results when Lab Normals are present Yes No | | Alkaline Pho | sphatase | | | No normals found |

Day 1 Impact to **Clinical Teams**

Yes

Visibility Data Manager, Lead Data Manager

on

Studio Updates

Overview

- Global Labs New Items being Added when Labs is enabled
 - Age (LBAGE), Sex (LBSEX), and Female Cycle (LBFEMALECYCLE)
 - New item LBSEX, use that in the eCRF, and add that to your casebook variable
 - No longer have to add the Lab_sex codelist to a Sex item. The Sex item is automatically created for you (LBSEX), but you still need to add it in the casebook variable.
- New Study created after 22R2 will be in the new Global Labs
 - Warning: Copying a study with the older Labs architecture model, it will create a new study with the old labs model. Migration to the new Labs Global Versionless Model will be necessary.
- Lab units and Lab codelists will no longer be created in Studio when the Lab panel is saved, since the Lab eCRFs will look directly to the Lab Module.

• Use case

The Lab Sex item will be created automatically, so users don't have to create it. And the new Global model will no longer have to sync to Studio, therefore creation of Lab Units and Codelists is not necessary.

Day 1 Impact to Clinical Teams

No

Visibility Study Designers

Configuration Studio

Dependencies

Labs Enabled New Studies Database Model 2

Summary

| Feature | Global Versionless (new model) | Study Level Version (old model) |
|---|--|---|
| Increasing Precision and Length | Config only in Labs | Config in Labs. Must be increased in Studio in New Casebook Version, Deployment, Retro- amendment |
| Lab Units | Config only in Labs | Config in Labs. Must be synched to Studio in New Casebook Version, Deployment, Retro-amendment |
| Lab Codelists | Config only in Labs | Config in Labs. Must be synched to Studio in New Casebook Version, Deployment, Retro-amendment |
| Lab Unit/Codelist Archive (hide) | Config only in Labs | Config in Labs. Must be hidden in Studio in New Casebook Version, Deployment, Retro-amendment |
| Lab Unit Conversions change post go live | Update conversion in Labs. Run Mass update - Update Translated Values | Config in Labs - Create a new lab unit item with the new lab unit conversion. Must be synched to Studio in New Casebook Version, Label the old unit item do not use. Deployment, Retro-amendment. |
| Lab Unit Standard change post go live | Update Standard in Labs. Run Mass update - Update Translated Values | Config in Labs - Create a new lab unit with the new lab unit standard. Must be synched to Studio in New Casebook Version, Label the old unit item do not use. Deployment, Retro-amendment. |
| Disable Unit selection for Lab Results when Lab Normals are Present | Same | Same |
| Audit Trail for Translated Values | Same | Same |


Lab Header Updates

Overview

For easier and streamlined data entry, the lab header has been updated to a new look and feel.

Use case

When entering data on a lab form, the collection date, lab location, age and sex will be left aligned, making it easier to enter data on smaller screens.



Yes

Visibility

Site Users

Configuration N/A



Data Entry

Data Entry Updates

Overview

- Event & Event Date in Item form Linking Dialog
- New icon for ILB
- Hint Labels in Detail & Closeout PDFs
- Use case
 - Consistency with data entry UI and UI/UX patterns

| Eligit | bility Criteria | | | | | | | |
|--------|-----------------|--------|-------------|-------------|--------------------------------------|---------------------------|-------------|-------------|
| | Signs | | | Linked Dosi | ing Data | | | |
| em | ographics | | | | | | | |
| (po | sure Oral | | | | | | | × |
| | | | | | | | | 1-2 of 2 |
| | Reference # | Event | Event Date | Start Date | Start Time | Actual Volume Administere | End Date | End Time |
| | 1 | Week 1 | 02-Jun-2022 | 02-Jun-2022 | 10:00 | 25 | 02-Jun-2022 | 10:30 |
| | 1 | Week 2 | 08-Jun-2022 | 08-Jun-2022 | 09:00 | 100 | 08-Jun-2022 | 09:45 |
| | | | | 1 | | | | |
| | | | | | | | | Cancel Save |
| Rest | ricted Data 🔍 | | | Planned Tir | nepoint | 2 Hour | Post-Dose | |
| Expo | osure Oral 🚺 | | | | | | | |
| | macokinetic | | | | sample collected at the specified ti | menoint? | res 🔿 No | |



Visibility Site Users

Configuration N/A

Dependencies

N/A

| • Fc | o n for ILB orm em Group | | Da | ata Entr | y Upd | ates | | | Day 1 Impact to Clinical Teams Yes |
|-------------------|---------------------------------------|--------------|-------------------|---------------------|--------------------|--------------|------|--------------------------|---|
| • Ite | em | | | | | | | | Visibility |
| Week 2 (08-Jun-20 | 22): Pharmacoki | netic | | | Complete •••• | | | | Site Users |
| Linked Dosing Dat | | | in a | ACTIONS | Blank | | | | |
| Linked Dosing Da | ta | | Select | Export Blank PDF | | | 18 | | |
| Pharmacokinetic | Pharmacokin | etic (1 of 5 | | | | | | | |
| rhannacokinette | Planned Time | epoint | ACTIONS | | t-Dose | | | | Configuration |
| | | | Intentional | y Left Blank | 1 | | | | N/A |
| | Was the PK s timepoint? | ample col | lected at the spe | cified O Yes | s O No | | | | |
| | Date and Tin | | | [· | Ĩ | 7 | | | n |
| | | | | ollected at the spe | cified | O Yes | O No | | |
| | | timepo | int? | | | - | - | ACTIONS | Dependencies |
| | | Date a | nd Time of Spe | cimen collection | | date | time | Intentionally Left Blank | N/A |
| V | | | | | opyright 🕲 veeva : | systems 2022 | | | 1 |

Data Entry Updates

Hint Labels in Detail & Closeout PDFs

| /ital Signs | |
|-----------------------------|------------------|
| Were Vital Signs collected? | 🗙 Yes 🔿 No 🚥 |
| Position | Standing |
| Date of Assessment | 02-May-2022 ···· |
| Height | Weight |
| 69 Inches 💌 | 185 Pounds 👻 |
| Body Mass Index | 27.3 |
| Respiration Rate | 55 bpm 👻 |
| Heart Rate | 36 bpm |
| Blood Pressure | 120 / 89 mmHg |

| Event: Screening Visit Day 1 Event Date: 02-May-2022 | |
|---|-------------|
| | |
| Form: Vital Signs | |
| Version: 1 | |
| Item | Value |
| Vital Signs | |
| Were Vital Signs collected? | Yes |
| Position | Standing |
| Date of Assessment | 02-May-2022 |
| Height | 69 Inches |
| Weight | 185 Pounds |
| Body Mass Index | 27.3 |
| Respiration Rate | 55 bpm |
| Heart Rate | 36 [bpm] |
| Systolic Blood Pressure | 120 |
| Diastolic Blood Pressure | 89 [mmHg] |

Form in EDC

Form in Detailed PDF

Day 1 Impact to Clinical Teams

Yes

Visibility Site Users

Configuration

N/A

Dependencies

N/A

Day 1 Impact to **Clinical Teams**



DMs

iration

lencies

Overview

- Form Link Audit Trail is available in Review
- PDs and Assessments in Audit Trail Export •
- Updated look & feel for PD Audit Trail •
- Event Audit Trail to include: •
 - Event Date _
 - Planned Date _
 - **Overdue** Date _
- Form Audit Trail to include:
 - Site _
 - Country —
- ۲ Entry in Form Audit if legal statement changes

Use case

Gives users more access to their audit data.

| | | | | Visibility |
|-----|---------------------------------------|--|--|-------------------|
| | Timestamp 6/27/2022 5:53:09 PM PDT | Usemame | Event Description | Site Users |
| 0 | /27/2022 5:53:09 PM PD1 | Margaret Wehner (margaret.wehner@mw.com) | "User Modified By" set to "Margaret Wehner" | |
| 6 | /27/2022 5:53:09 PM PDT | Margaret Wehner (margaret.wehner@rnw.com) | "Date of Deviation" set to "2022-06-01" | CRAs, DMs |
| 6/2 | 27/2022 5:53:09 PM PDT | Margaret Wehner (margaret.wehner@mw.com) | "Protocol Deviation Status" changed from "Open" to "Investigating" | |
| 6/ | /27/2022 5:53:09 PM PDT | Margaret Wehner (margaret.wehner@mw.com) | "User Modified Date" set to "2022-06-28T00:53:09.000Z" | |
| 6/8 | 8/2022 4:11:30 PM PDT | Margaret Wehner (margaret.wehner@mw.com) | Protocol Deviation : PDV-000032 created | |
| | | | | Configuratio |
| | | | | |
| | | | | N/A |
| | | | | N/A |
| | | | | N/A |
| | | | Close | N/A |
| | | | Close | N/A |
| | | | Close | N/A Dependenci |

Form Link Audit Trail in Review

| | 01 | Timestamp | Username System on behalf of Margare (margaret.wehner@mw.com | | Event Description Screening Visit Day 1/Demographics link to Screening Visit Day 1/Pregnancy Test dele |
|-------------|---|------------------------------|--|---|---|
| | 01 | | Username | | Event Description |
| | | Freghancy vital Signs | | | |
| | | Pregnancy Vital Signs | | | |
| Race check | c all that apply | orm Link Audit Trail | | | |
| Ethnicity | Form Audit Trail Form Link Audit Trail | Not Hispanic or LatinX | | | |
| Sex | VIEW | Female | | 0 | |
| Age at Time | | 28 | | 0 | |
| Birth Date | Create Protocol Deviation | 01-Mar-1994 | | 0 | |
| Demograph | Freeze Form Lock Form | | | 0 | |
| | ACTIONS | | | | - |
| Demograph | 🕸 Freeze Form | GNANCY (1) & VITAL SIGNS (1) | | 0 | - |

Day 1 Impact to **Clinical Teams**

Yes

Visibility Site Users, CRAs, DMs

Configuration N/A

Dependencies

N/A

PDs and Assessments in Audit Trail Export

| Day 1 |
|-----------------------|
| Impact to |
| Clinical Teams |

Yes

Visibility Site Users, CRAs, DMs

| Audit Timestamp | Audit User | ▼ Assessment ▼ | Object | T Record ID 🔻 | Record Name 3 | Audit Description |
|--------------------------|--|-----------------------|--------------------|---------------|--------------------------|---|
| 14-May-2022 01:18:36 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000023 | Pregnant Patient | Protocol Deviation : PDV-000023 created |
| 14-May-2022 01:18:53 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000024 | Date of Informed Consent | Protocol Deviation : PDV-000024 created |
| 20-May-2022 00:18:42 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000023 | Pregnant Patient | "Description" set to "Patient was positive on first test, but negative on second test" |
| 20-May-2022 00:18:42 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000023 | Pregnant Patient | "User Modified Date" set to "2022-05-20T00:18:42.000Z" |
| 20-May-2022 00:18:42 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000023 | Pregnant Patient | "Protocol Deviation Status" changed from "Open" to "Investigating" |
| 20-May-2022 00:18:42 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000023 | Pregnant Patient | "Date of Deviation" set to "2022-05-02" |
| 20-May-2022 00:18:42 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000023 | Pregnant Patient | "User Modified By" set to "Margaret Wehner" |
| 20-May-2022 00:19:22 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000024 | Date of Informed Consent | "User Modified Date" set to "2022-05-20T00:19:22.000Z" |
| 20-May-2022 00:19:22 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000024 | Date of Informed Consent | Protocol Deviation Status" changed from "Open" to "Investigating" |
| 20-May-2022 00:19:22 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000024 | Date of Informed Consent | T "Date of Deviation" set to "2022-05-02" |
| 20-May-2022 00:19:22 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000024 | Date of Informed Consent | t "User Modified By" set to "Margaret Wehner" |
| 20-May-2022 00:26:01 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000024 | Date of Informed Consent | "Resolution" set to "Data entry error - Informed consent was signed at the screening visit." |
| 20-May-2022 00:26:01 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000024 | Date of Informed Consent | "User Modified Date" changed from "2022-05-20T00:19:22.000Z" to "2022-05-20T00:26:01.000Z" |
| 20-May-2022 00:26:01 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000024 | Date of Informed Consent | Protocol Deviation Status" changed from "Investigating" to "Inactive" |
| 20-May-2022 00:26:01 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000024 | Date of Informed Consent | "Last Inactivated Date" set to "2022-05-20T00:26:01.000Z" |
| 20-May-2022 00:26:01 UT | Margaret Wehner (margaret.wehner@mw.com) | | Protocol Deviation | PDV-000024 | Date of Informed Consent | "Inactivated By System" set to "false" |
| 09-Jun-2022 03:27:46 UTC | System | serious_adverse_event | Assessment | VV-000019 | serious_adverse_event | Assessment : VV-000019 created |
| 09-Jun-2022 03:27:48 UTC | System | serious_adverse_event | Assessment Respons | e VV-000028 | Comment | Assessment Response : VV-000028 created |
| 09-Jun-2022 03:27:48 UTC | System | serious_adverse_event | Assessment Respons | e VV-000029 | SAE_Number | Assessment Response : VV-000029 created |
| 28-Jun-2022 00:08:05 UTC | Margaret Wehner (margaret.wehner@mw.com) | serious_adverse_event | Assessment Respons | e VV-000028 | Comment | "Answer" set to "Yes, this is a serious adverse event. Please reconcile with pharmacovigilance database." |
| 28-Jun-2022 00:08:05 UTC | Margaret Wehner (margaret.wehner@mw.com) | serious_adverse_event | Assessment Respons | e VV-000029 | SAE_Number | "Answer" set to "123" |

Configuration N/A

Dependencies

N/A

Event Audit Trail Updates

| vent Audit Trail | |) |
|--------------------------|---|--|
| Timestamp | Username | Event Description |
| 6/10/2022 1:22:05 PM PDT | System | "Event Date SDV Mode" set to "Required |
| 6/10/2022 1:22:03 PM PDT | System on behalf of Margaret Wehner (margaret.wehner@mw.com) | "Planned Date" set to "2022-06-10" |
| 6/10/2022 1:22:03 PM PDT | System on behalf of Margaret Wehner (margaret.wehner@mw.com) | "Overdue Date" set to "2022-06-12" |
| 6/10/2022 1:22:03 PM PDT | System on behalf of Margaret Wehner (margaret.wehner@mw.com) | Event : VV-001145 created |

| Event Audit Trail | | | | | | | |
|--------------------------|---|--|--|--|--|--|--|
| Timestamp | Username | Event Description | | | | | |
| 6/27/2022 6:12:39 PM PDT | System | "Event Date SDV Mode" set to "Required | | | | | |
| 6/27/2022 6:12:38 PM PDT | System on behalf of Margaret Wehner (margaret.wehner@mw.com) | "Event Date" set to "2022-06-11" | | | | | |
| 6/27/2022 6:12:38 PM PDT | System on behalf of Margaret Wehner (margaret.wehner@mw.com) | Event : VV-001169 created | | | | | |

Scheduled Offset Events

Unscheduled Events

Day 1 Impact to Clinical Teams

Yes

Visibility Site Users, CRAs, DMs

Configuration N/A

Dependencies

N/A



Form Audit Trail Updates

| orm Audit Trail | | | |
|-------------------------|---|--|--|
| imestamp | Username | Event Description | |
| /27/2022 6:15:30 PM PDT | System on behalf of Margaret Wehner (margaret.wehner@mw.com) | Form unsigned | |
| /27/2022 6:15:30 PM PDT | Margaret Wehner (margaret.wehner@mw.com) | The signature was invalidated because of a change in attestation statement | |
| /3/2022 10:48:18 AM PDT | Margaret Wehner (margaret.wehner@mw.com) | Form signed. Signature Meaning: By entering my electronic signature, I attest data entries in this Case Report Form and have determined that they are com compatible with source documents. I verify all of this to be true. | |
| /2/2022 11:57:42 AM PDT | System on behalf of Margaret Wehner (margaret.wehner@mw.com) | "Study Country" changed from "Belgium" to "United States" | |
| /2/2022 11:57:42 AM PDT | System on behalf of Margaret Wehner (margaret.wehner@mw.com) | "Site" changed from "04" to "01" | |
| /2/2022 10:22:32 AM PDT | Margaret Wehner (margaret.wehner@mw.com) | "Form Status" changed from "In Progress" to "Submitted" | |
| /2/2022 10:22:32 AM PDT | Margaret Wehner (margaret.wehner@mw.com) | "Submission Date" set to "2022-06-02T17:22:32.000Z" | |
| /2/2022 10:22:32 AM PDT | Margaret Wehner (margaret.wehner@mw.com) | "Number of Submits" changed from "0" to "1" | |
| /2/2022 10:22:30 AM PDT | Margaret Wehner (margaret.wehner@mw.com) | "Form Status" changed from "Blank" to "In Progress" | |
| 70/0000 10-00-30 AM DIT | Svetam on habalf of Managat Wahner | "Earada" channed from "true" to "falce" | |

copyright & veeva bystems 2022

Day 1 Impact to Clinical Teams

Yes

Visibility Site Users, CRAs, DMs

Configuration N/A

Dependencies

N/A

Close



Reassessment

Reassessment

Day 1 Impact to Clinical Teams

No

Visibility Study Designers

Configuration Studio

Dependencies

Data Model 2

Overview

- New Reassessment tab in the assessment definition in Studio that allows the user to choose which visible items should trigger a reassessment when data changes
- Reassessment only opens when the previous assessment is completed
- Previous assessment is made obsolete and new assessment is opened and marked as a reassessment

Use case

When data changes since the last assessment, a new assessment will open allowing an assessor to make an assessment on the latest data.

Assessment Enhancements



- Can't complete or edit assessments when study/site is locked
- Warning when locking a site with open assessments

Use case

When a study or site is locked, users are no longer able to change assessment data.

| 1 | |
|----------------|--|
| 1 | |
| Active Version | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| | |

Yes

Visibility Assessment Editors, Admins

Configuration N/A

Dependencies

Assessments

Assessment Enhancements

Day 1 Impact to Clinical Teams

Yes

Visibility Assessment Editors, Admins

| Back to all Assessments | | | | • |
|-------------------------------------|-----------------------------------|---|--------------|--|
| Serious Adverse Event | | | | |
| Study Site Number Demomine _DEV1 01 | Subject Event 04-003 Log Forms | Form Status Adverse Events (1) Completed | Reassessment | |
| Snapshot View of Data as of 27- | Jun-2022 05:08 PM | | | This action cannot be performed because this site is locked |
| Schedule | Adverse Events: Reference #* | l of 1 📕 🍝 🔻 View Summary | | Comment |
| ✓ Screening Visit Day 1 03-May-2022 | Adverse Events | | | Yes, this is a serious adverse event. Please reconcile with pharmacovigilance database. |
| Vital Signs | Adverse Event | Internal bleeding | | Number value 123 |
| Medical History | Start Date | 08-Jun-2022 | | |
| - Week 1 04-May-2022 | Ongoing? | Yes | | |
| Vital Signs | | | | |
| ✓Log Forms | End Date | | | |
| Adverse Events (1) 📕 | Severity | Severe | | |
| | Toxicity Grade | Life Threatening (Grad | de 4) | |
| | Serious? | Yes | | |
| | Relationship to Study Treatme | ent Yes | | |
| | Action Taken with Study Treat | ment Drug Withdrawn | | |

Dependencies

Configuration N/A

Assessments



Reports

Study Summary Metrics Report


• Overview

The Study Summary Metrics Report will summarize how much SDV and DMR has occurred in the study at the site and country levels.

It will include the number of sites, subjects, events and forms that are reviewed and calculate the percentage of review completed.

Use case

This report summarizes how much SDV and DMR has been completed in the study and how much work is still remaining.



Review Rollup V2

Dependencies

Day 1 Impact to

Clinical Teams

No

Study Summary Metrics Report

Study Country Aggregates

%

1

0

0

Total Subjects Subjects SDV Subjects SDV Total Events Events SDV

20

0

0

8

2

25

2

1

5

Total Forms Forms SDV

21

7

69

8

6

24

SDV Required Complete Events SDV % SDV Required Complete Forms SDV % Listing

25

50

20

Day 1 Impact to Clinical Teams



Visibility CRA, DM, Lead Data Manager

Last Run of

38 6/28/22 1:20

85 6/28/22 1:20

34 6/28/22 1:20

Study Country Aggregates

| Study | Study Country | Study Site | Total Subjects SDV Required | | Subjects SDV % | Total Events SDV Required | Events SDV Complete | Events SDV % | Total Forms SDV Required | Forms SDV Complete | Forms SDV % | Last Run of Listing |
|----------------|---------------|------------|--------------------------------|---|-------------------|------------------------------|------------------------|--------------|-----------------------------|-----------------------|-------------|------------------------|
| Demomine _DEV1 | United States | UCSF | 7 | 0 | 0 |) 19 | | 2 10 | 55 | 13 | 23 | 6/28/22 1:20 |
| Demomine _DEV1 | United States | NHS | 3 | 0 | 0 |) 6 | | 3 50 | 14 | 11 | 78 | 6/28/22 1:20 |
| Demomine _DEV1 | Belgium | Antwerp | 5 | 1 | 20 | 8 (8 | | 2 25 | 21 | . 8 | 38 | 6/28/22 1:20 |
| Demomine _DEV1 | Germany | Berlin | 1 | 0 | 0 |) 2 | | 1 50 | 7 | 6 | 85 | 6/28/22 1:20 |

Configuration N/A

Dependencies

Review Rollup V2



Study

Demomine _DEV1 Belgium

Demomine DEV1 Germany

Demomine _DEV1 United States

Total Sites

Sites SDV

1

1

2

Study Country SDV Required Complete Sites SDV % SDV Required Complete

0

0

0

0

0

0

5

1

10

Event Progress Listing - Review Data

• Overview

The Study Summary Metrics Report will summarize how much SDV and DMR has occurred in the study at the site and country levels. It will include the number of sites, subjects, events and forms that are reviewed and calculate the percentage of review completed.

Use case

The Event Progress Listing will now provide a high level summary of how events are progressing throughout the study, with additional information about how much SDV and DMR has been completed.

| New | × |
|-------------------------------------|----------------|
| Туре | Frequency |
| Event Progress Listing - | Run Now 👻 |
| Include Restricted Data | |
| Include Review Data | |
| Execute for all countries and sites | |
| Select countries | |
| O Select sites | |
| | Cancel Run Now |

Day 1 Impact to Clinical Teams

No

Visibility CRA, DM, Lead Data Manager

Configuration N/A

Dependencies

Review Rollup V2

Event Progress Listing - Review Data

Day 1 Impact to Clinical Teams

No

Visibility CRA, DM, Lead Data Manager

Configuration N/A

Dependencies

Review Rollup V2

| D | E | F | G | S | т | U | V | W | Х | Y | Z |
|---------|----------------|-------------------|-----------------------|--------------------|----------------|-------------------------|---------------------|--------------------------|----------------------------|-------------|-----------------------|
| Subject | Subject Status | Event Group Label | Event Label | SDV Plan | Event Date SDV | Event Date SDV Required | Event Date SDV Date | Total Forms SDV Complete | Total Forms - SDV Required | % Forms SDV | SDV Completion Date [|
| 03-001 | Enrolled | Screening Visit | Screening Visit Day 1 | Treatment SDV Plan | Y | Required | 5/20/22 22:56 | 4 | 4 | 100 | 5/20/22 22:56 |
| 03-001 | Enrolled | Log Form Prompts | Log Forms | Treatment SDV Plan | | | | 0 | 1 | 0 | |
| 03-001 | Enrolled | Treatment | Week 1 | Treatment SDV Plan | N | Required | | 0 | 0 | | |
| 03-001 | Enrolled | Treatment | Week 2 | Treatment SDV Plan | N | Required | | 0 | 0 | | |
| 03-001 | Enrolled | Treatment | Week 3 | Treatment SDV Plan | N | Required | | 0 | 0 | | |
| 03-001 | Enrolled | Treatment | Week 4 | Treatment SDV Plan | N | Required | | 0 | 0 | | |
| 03-001 | Enrolled | Treatment | Week 5 | Treatment SDV Plan | N | Required | | 0 | 0 | | |
| 03-002 | In Screening | Screening Visit | Screening Visit Day 1 | Treatment SDV Plan | N | Required | | 4 | 4 | 100 | 6/3/22 18:05 |
| 03-002 | In Screening | Log Form Prompts | Log Forms | Treatment SDV Plan | | | | 2 | 3 | 66 | |
| 03-002 | In Screening | Treatment | Week 1 | Treatment SDV Plan | N | Required | | 1 | 1 | 100 | 6/3/22 18:05 |
| 03-002 | In Screening | Treatment | Week 2 | Treatment SDV Plan | N | Required | | 0 | 0 | | |
| 03-002 | In Screening | Treatment | Week 3 | Treatment SDV Plan | N | Required | | 0 | 0 | | |
| 03-002 | In Screening | Treatment | Week 4 | Treatment SDV Plan | N | Required | | 0 | 0 | | |
| 03-002 | In Screening | Treatment | Week 5 | Treatment SDV Plan | N | Required | | 0 | 0 | | |
| 01-002 | Enrolled | Screening Visit | Screening Visit Day 1 | Full SDV Plan | Y | Required | 5/24/22 22:50 | 4 | 7 | 57 | |
| 01-002 | Enrolled | Treatment | Week 1 | Full SDV Plan | Y | Required | 5/17/22 22:49 | 3 | 3 | 100 | 5/24/22 22:49 |
| 01-003 | Screen Failure | Screening Visit | Screening Visit Day 1 | Treatment SDV Plan | Y | Required | 5/20/22 22:49 | 4 | 5 | 80 | |
| 01-002 | Enrolled | Treatment | Week 2 | Full SDV Plan | N | Required | | 0 | 1 | 0 | |
| 01-002 | Enrolled | Treatment | Week 3 | Full SDV Plan | N | Required | | 0 | 0 | | |
| 01-002 | Enrolled | Treatment | Week 4 | Full SDV Plan | N | Required | | 0 | 0 | | |
| 01-002 | Enrolled | Treatment | Week 5 | Full SDV Plan | N | Required | | 0 | 0 | | |
| 01-002 | Enrolled | Log Form Prompts | Log Forms | Full SDV Plan | | | | 0 | 4 | 0 | |
| 01-004 | In Screening | Screening Visit | Screening Visit Day 1 | Treatment SDV Plan | Y | Required | 5/17/22 22:49 | 1 | 1 | 100 | 5/17/22 22:49 |
| 01-004 | In Screening | Log Form Prompts | Log Forms | Treatment SDV Plan | | | | 0 | 2 | 0 | |

Study Progress Listing Enhancements

• Form Progress Listing

SDV and DMR columns are renamed to SDV Complete and DMR Complete

Use case

This will help clarify if SDV or DMR was completed for a form.

| Т | U | V | W | х | Y | Z | AA | AB | AC | AD | AE |
|--------------------|-------------------|--------------|--------------|------------------------------|--------------------|-------|---------|---------------|----------|-------------------|--------------|
| SDV Plan | SDV Override Plan | SDV Complete | SDV Required | Items SDV Required Completed | Items SDV Required | SDV % | SDV Age | SDV Date | DMR Plan | DMR Override Plan | DMR Complete |
| Treatment SDV Plan | | Yes | Yes | 2 | 2 | 100 | | 5/20/22 22:56 | | | No |
| Treatment SDV Plan | | Yes | Yes | 1 | 1 | 100 | | 5/20/22 22:56 | | | No |
| Treatment SDV Plan | | Yes | Yes | 3 | 3 | 100 | | 5/20/22 22:56 | | | No |
| Treatment SDV Plan | | No | No | 0 | 0 | | | | | | No |
| Treatment SDV Plan | | Yes | Yes | 4 | 4 | 100 | | 5/20/22 22:56 | | | No |
| Treatment SDV Plan | | No | No | 0 | 0 | | | | | | No |
| Treatment SDV Plan | | No | No | 0 | 0 | | | | | | No |

No

Visibility CRA, DM, Lead Data Manager

Configuration N/A

Dependencies

N/A

• Overview

With the Additive Review Listing, users can report on how much additive review was performed in the study during a specific time period.

In the listing, there will be a summary of the items and event dates reviewed. Additionally, there will be a detailed report of the additively reviewed items and dates, answering who performed the review, when and the reason why.

Use case

This listing will summarize how much additive review was performed in a study during a specific time period and why. It will allow users to identify sites with high and low amounts of review or CRAs and Data Managers performing review outside of their required duties.

Day 1 Impact to Clinical Teams

No

Visibility CRA, DM, Lead Data Manager

Configuration Studio

Dependencies

Additive Review enabled



| New | × | NO |
|-------------------------------------|--|--------------------|
| Туре | Frequency | |
| Additive Review Listing - | Monthly | Visibility |
| Review Task | Name | CRA, DM, Lead |
| SDV | Monthly Additive Review Report | Data Manager |
| DMR Date Range | Run at | |
| Last 30 days | 12:00 AM 👻 | |
| | Repeat monthly on day | Configuration |
| Include Restricted Data | 1 🔹 | Studio |
| Execute for all countries and sites | Active Periods | |
| Select countries | 1 | |
| Select sites | Scheduled jobs will be removed once the number of active periods has been reached. | Dependencies |
| | Cancel Schedule | Additive Review |

Day 1 Impact to **Clinical Teams**

No

enabled

V

Copyright © Veeva Systems 2022

Additive Review Summary

| Country | | Number of Items Additively SDV | | |
|--------------|------|--------------------------------|--|--|
| Belgium | | 73 | | |
| Germany | | 14 | | |
| United State | S | 37 | | |
| Country | Site | Number of Items Additively SDV | | |
| Belgium | 4 | 73 | | |
| Germany | 5 | 14 | | |
| United State | 1 | 14 | | |
| United State | 3 | 23 | | |

Day 1 Impact to Clinical Teams

No

Visibility CRA, DM, Lead Data Manager

Configuration Studio

Dependencies

Additive Review enabled



Additive Review Summary

| item Label | Review Plan Type | Last Reviewed By | Last Reviewed Date | Additive Reason | Last Run of Listing |
|---|---------------------|------------------|-----------------------|----------------------------------|------------------------|
| Is the subject of childbearing potential? | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Other | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Postmenopausal | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Premenarchal | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Specify Other Reason for Non-childbearing Potential | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Surgically Sterile | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Black or African American | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Asian | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Ethnicity | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Native American or Alaska Native | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Native Hawaiian or Other Pacific Islander | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Other | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| White | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Were Vital Signs collected? | SDV | Cathy CRA | 2022-05-20T22:49Z | Evidence of transcription errors | 6/28/22 1:32 |
| Is the subject of childbearing potential? | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Other | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Postmenopausal | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Premenarchal | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Specify Other Reason for Non-childbearing Potential | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Surgically Sterile | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Black or African American | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Age at Time of Informed Consent | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Asian | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Birth Date | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Ethnicity | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Native American or Alaska Native | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Native Hawaiian or Other Pacific Islander | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Other | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |
| Sex | SDV | Margaret Wehner | 2022-05-20T22:56Z | Source quality | 6/28/22 1:32 |

Day 1 Impact to Clinical Teams

No

Visibility CRA, DM, Lead Data Manager

Configuration Studio

Dependencies

Additive Review enabled



Copyright © Veeva Systems 2022

Dedicated DEMO

For a dedicated demo of any these features, please contact your Account Executive OR Customer Success Manager



Thank you